Norden Group LLC Takes $59,000 Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Norden Group LLC purchased a new stake in Ventyx Biosciences, Inc. (NASDAQ:VTYXFree Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 10,685 shares of the company’s stock, valued at approximately $59,000.

Other hedge funds have also modified their holdings of the company. Opaleye Management Inc. acquired a new position in Ventyx Biosciences during the fourth quarter worth $2,816,000. Hudson Bay Capital Management LP raised its holdings in Ventyx Biosciences by 160.2% during the third quarter. Hudson Bay Capital Management LP now owns 248,515 shares of the company’s stock worth $8,631,000 after purchasing an additional 153,000 shares during the last quarter. Vanguard Group Inc. raised its holdings in Ventyx Biosciences by 11.7% during the third quarter. Vanguard Group Inc. now owns 2,662,671 shares of the company’s stock worth $92,475,000 after purchasing an additional 277,906 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Ventyx Biosciences in the fourth quarter worth $323,000. Finally, Federated Hermes Inc. acquired a new position in shares of Ventyx Biosciences in the fourth quarter worth $50,000. 97.88% of the stock is owned by institutional investors and hedge funds.

Ventyx Biosciences Stock Up 4.3 %

Shares of NASDAQ:VTYX opened at $2.44 on Thursday. The company has a market cap of $172.02 million, a P/E ratio of -0.75 and a beta of 0.39. Ventyx Biosciences, Inc. has a 52 week low of $1.87 and a 52 week high of $38.20. The business has a fifty day simple moving average of $3.63 and a 200-day simple moving average of $4.13.

Ventyx Biosciences (NASDAQ:VTYXGet Free Report) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.05. During the same period in the previous year, the company posted ($0.68) earnings per share. Sell-side analysts expect that Ventyx Biosciences, Inc. will post -2.31 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Canaccord Genuity Group cut their price target on Ventyx Biosciences from $16.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday, March 13th. HC Wainwright reissued a “neutral” rating and issued a $6.00 price target on shares of Ventyx Biosciences in a report on Thursday, June 13th. Finally, Oppenheimer cut their price target on Ventyx Biosciences from $12.00 to $10.00 and set an “outperform” rating for the company in a report on Thursday, June 6th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $15.75.

View Our Latest Research Report on VTYX

Ventyx Biosciences Company Profile

(Free Report)

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

Featured Stories

Institutional Ownership by Quarter for Ventyx Biosciences (NASDAQ:VTYX)

Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.